Evidence map›Paper›PMID 27936049›Full record

ArticlePloS one2016

Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.

Chenlei Shi, Yong Guo, Yichen Lv, Abiyasi Nanding, Tiefeng Shi, Huadong Qin, Jianjun He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Risk and Prognostic Factors for BRAFBioMed research international · 2022
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. BRAFWorld journal of surgical oncology · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chenlei ShiDepartment of breast surgery, the First Affiliated Hospital, Xi'an Jiao Tong University, Xi'an, China.
Yong GuoDepartment of Breast and Thyroid, Heze Municipal Hospital, Shandong Province, Heze, China.
Yichen LvThe Fourth Department of General Surgery, the Second Affiliated Hospital, Harbin Medical University, Harbin, China.
Abiyasi NandingThe Pathology Department, the Third Affiliated Hospital, Harbin Medical University, Harbin, China.
Tiefeng ShiThe Fourth Department of General Surgery, the Second Affiliated Hospital, Harbin Medical University, Harbin, China.
Huadong QinThe Fourth Department of General Surgery, the Second Affiliated Hospital, Harbin Medical University, Harbin, China.
Jianjun HeDepartment of breast surgery, the First Affiliated Hospital, Xi'an Jiao Tong University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinicopathological characteristics of papillary thyroid microcarcinoma (PTMC) for surgery by comparing the difference between PTMC and larger papillary thyroid carcinoma (LPTC).

methodsWe analyzed the differences in the clinicopathological characteristics, prognosis, B-type RAF kinase (BRAF)V600E mutational status and expression of angiogenic factors, including pigment epithelium-derived factor (PEDF), Vascular Endothelial Growth Factor (VEGF), and hypoxia-inducible factor alpha subunit (HIF-1α), between PTMC and LPTC by retrospectively reviewing the records of 251 patients with papillary thyroid carcinoma, 169 with PTMC, and 82 with LPTC (diameter >1 cm).

resultsThere were no significant differences in the gender, age, multifocality, Hashimoto's thyroiditis, TNM stage, PEDF protein expression, rate of recurrence, or mean follow-up duration between patients with PTMC or LPTC. The prevalence of extrathyroidal invasion (EI), lymph node metastasis (LNM), and BRAF mutation in patients with PTMC was significantly lower than in patients with LPTC. In addition, in PTMC patients with EI and/or LNM and/or positive BRAF (high-risk PTMC patients), the prevalence of extrathyroidal invasion, Hashimoto's disease, lymph node metastasis, tumor TNM stage, PEDF positive protein expression, the rate of recurrent disease, and the mRNA expression of anti-angiogenic factors was almost as high as in patients with larger PTC, but with no significant difference.

conclusionsExtrathyroid invasion, lymph node metastases, and BRAFV600E mutation were the high risk factors of PTMC. PTMC should be considered for the same treatment strategy as LPTC when any of these factors is found. Particularly, PTMC with BRAFV600E gene mutations needed earlier surgical treatment. In addition, the high cell subtype of PTMC with BRAFV600E gene mutation is recommended for total thyroidectomy in primary surgery to reduce the risk of recurrence.

Indexed as

Gene Expression Regulation, NeoplasticPoint MutationAdultCarcinomaCarcinoma, PapillaryEye ProteinsFemaleHumansHypoxia-Inducible Factor 1, alpha SubunitLymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalNerve Growth FactorsPigment Epithelium-Derived FactorPrognosisBRAF protein, humanEye ProteinsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitNerve Growth FactorsPigment Epithelium-Derived FactorProto-Oncogene Proteins B-rafSerpinsVascular Endothelial Growth Factor A

Identifiers

PMID27936049
PMCPMC5147869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.